Menu Search
Equities

Actinium Pharmaceuticals Inc

7AY1:BER

Actinium Pharmaceuticals Inc

Actions
  • Price (EUR)6.88
  • Today's Change0.015 / 0.22%
  • Shares traded1.00k
  • 1 Year change-14.06%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 13:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

  • Revenue in USD (TTM)81.00k
  • Net income in USD-46.45m
  • Incorporated2013
  • Employees49.00
  • Location
    Actinium Pharmaceuticals Inc100 Park Ave., 23Rd FloorNEW YORK 10017United StatesUSA
  • Phone+1 (646) 677-3870
  • Fax+1 (845) 818-3588
  • Websitehttps://www.actiniumpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.